TY - JOUR
T1 - Endorsement of the OMERACT core domain set for shared decision making interventions in rheumatology trials
T2 - Results from a multi-stepped consensus-building approach
AU - Toupin-April, Karine
AU - Decary, Simon
AU - Wit, Maarten de
AU - Meara, Alexa
AU - Barton, Jennifer L.
AU - Fraenkel, Liana
AU - Li, Linda C.
AU - Brooks, Peter
AU - Shea, Beverly
AU - Stacey, Dawn
AU - Legare, France
AU - Lydiatt, Anne
AU - Hofstetter, Cathie
AU - Proulx, Laurie
AU - Christensen, Robin
AU - Voshaar, Marieke
AU - Suarez-Almazor, Maria E.
AU - Boonen, Annelies
AU - Meade, Tanya
AU - March, Lyn
AU - Jull, Janet Elizabeth
AU - Campbell, Willemina
AU - Alten, Rieke
AU - Morgan, Esi M.
AU - Kelly, Ayano
AU - Kaufman, Jessica
AU - Hill, Sophie
AU - Maxwell, Lara J.
AU - Guillemin, Francis
AU - Beaton, Dorcas
AU - El-Miedany, Yasser
AU - Mittoo, Shikha
AU - Robertson, Tiffany Westrich
AU - Bartlett, Susan J.
AU - Singh, Jasvinder A.
AU - Mannion, Melissa
AU - Nasef, Samah Ismail
AU - Souza, Savia de
AU - Boel, Anne
AU - Adebajo, Adewale
AU - Arnaud, Laurent
AU - Gill, Tiffany K.
AU - Moholt, Ellen
AU - Burt, Jennifer
AU - Jayatilleke, Arundathi
AU - Hmamouchi, Ihsane
AU - Carrott, David
AU - Blanco, Francisco J.
AU - Mather, Kate
AU - Maharaj, Ajesh
AU - Sharma, Saurab
AU - Caso, Francesco
AU - Fong, Christopher
AU - Fernandez, Anthony P.
AU - Mackie, Sarah
AU - Nikiphorou, Elena
AU - Jones, Allyson
AU - Greer-Smith, Regina
AU - Sloan, Victor S.
AU - Akpabio, Akpabio
AU - Strand, Vibeke
AU - Umaefulam, Valerie
AU - Monti, Sara
AU - Melburn, Charmaine
AU - Abaza, Nouran
AU - Schultz, Kirsten
AU - Stones, Simon
AU - Kiwalkar, Sonam
AU - Srinivasalu, Hemalatha
AU - Constien, Deb
AU - King, Lauren K.
AU - Tugwell, Peter
N1 - Funding Information:
Funding for travel awards to the OMERACT conference were provided by OMERACT . This funding was reported to OMERACT 2022 because of the Covid-19 pandemic. K. Toupin-April is funded by The Arthritis Society , the Chronic Pain Network (a Network funded by the Canadian Institutes of Health Research (CIHR) Strategy for Patient Oriented Research (SPOR), the Ontario Ministry of Economic Development , Job Creation and Trade and the Children's Hospital of Eastern Ontario Research Institute. S. Décary received a Banting postdoctoral salary award from Canadian Institutes for Health Research. J. L. Barton's research reported in this publication was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases, part of the National Institutes of Health , under Award Number K23AR-064372 . L. Fraenkel's research reported in this publication was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases, part of the National Institutes of Health , under Award Number AR060231– 01 . The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. L. C. Li holds the Harold Robinson/Arthritis Society Chair in Arthritic Diseases, and is supported by the Canada Research Chair Program. D. Stacey holds a University of Ottawa Research Chair in Knowledge Translation to Patients. F. Légaré holds a Tier 1 Canada Research Chair in Shared Decision Making and Knowledge Translation. R. Christensen's research at the Parker Institute is supported by grants from The Oak Foundation ( OCAY-13–309 ). L. March's research is supported by the Northern Sydney Local Health District. S. Hill is supported by La Trobe University. P. Tugwell holds a Canada Research Chair.
Funding Information:
The authors would like to thank Shawna Grosskleg, Laure Gossec, Sarah Collins, Thomas Chong, Pamela Richards, Ailsa Bosworth, Pamela Montie, Jennifer Petkovic, Vicki Evans, C?cile Gaujoux-Viala, Anne Stiggelbout, Suvi Karuranga, Ian M. Disend and Andrea Boyd. We would like to thank the Canadian Arthritis Patient Alliance (CAPA), the EULAR PARE (People with Arthritis and Rheumatism) network and EULAR PRPs, GRAPPA (Group for Research of Psoriasis and Psoriatic Arthritis) PRPs, the International Foundation for Autoimmune & Autoinflammatory Arthritis (AiArthritis), Creaky Joints, Joint Health, SAVVY Coop, S.T.A.R Initiative, the Childhood Arthritis and Rheumatology Research Alliance (CARRA), the Cochrane Musculoskeletal consumer group, Versus Arthritis UK, Arthritis Care Netherlands, Vasculitis UK, Osteoarthritis Research Society International (OARSI), Dragon Claw and the Canadian Rheumatology Association. Funding for travel awards to the OMERACT conference were provided by OMERACT. This funding was reported to OMERACT 2022 because of the Covid-19 pandemic. K. Toupin-April is funded by The Arthritis Society, the Chronic Pain Network (a Network funded by the Canadian Institutes of Health Research (CIHR) Strategy for Patient Oriented Research (SPOR), the Ontario Ministry of Economic Development, Job Creation and Trade and the Children's Hospital of Eastern Ontario Research Institute. S. D?cary received a Banting postdoctoral salary award from Canadian Institutes for Health Research. J. L. Barton's research reported in this publication was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases, part of the National Institutes of Health, under Award Number K23AR-064372. L. Fraenkel's research reported in this publication was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases, part of the National Institutes of Health, under Award Number AR060231? 01. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. L. C. Li holds the Harold Robinson/Arthritis Society Chair in Arthritic Diseases, and is supported by the Canada Research Chair Program. D. Stacey holds a University of Ottawa Research Chair in Knowledge Translation to Patients. F. L?gar? holds a Tier 1 Canada Research Chair in Shared Decision Making and Knowledge Translation. R. Christensen's research at the Parker Institute is supported by grants from The Oak Foundation (OCAY-13?309). L. March's research is supported by the Northern Sydney Local Health District. S. Hill is supported by La Trobe University. P. Tugwell holds a Canada Research Chair.
Publisher Copyright:
© 2021 Elsevier Inc.
PY - 2021/6
Y1 - 2021/6
N2 - Objective: To gain consensus on the Outcome Measures in Rheumatology (OMERACT) core domain set for rheumatology trials of shared decision making (SDM) interventions.Methods: The process followed the OMERACT Filter 2.1 methodology, and used consensus-building methods, with patients involved since the inception. After developing the draft core domain set in previous research, we conducted five steps: (i) improving the draft core domain set; (ii) developing and disseminating whiteboard videos to promote its understanding; (iii) conducting an electronic survey to gather feedback on the draft core domain set; (iv) finalizing the core domain set and developing summaries, a plenary session video and discussion boards to promote its understanding; and (v) conducting virtual workshops with voting to endorse the core domain set.Results: A total of 167 participants from 28 countries answered the survey (62% were patients/caregivers). Most participants rated domains as relevant (81%-95%) and clear (82%-93%). A total of 149 participants (n = 48 patients/caregivers, 101 clinicians/researchers) participated in virtual workshops and voted on the proposed core domain set which received endorsement by 95%. Endorsed domains are: 1-Knowledge of options, their potential benefits and harms; 2-Chosen option aligned with each patient's values and preferences; 3-Confidence in the chosen option; 4-Satisfaction with the decision-making process; 5-Adherence to the chosen option and 6-Potential negative consequences of the SDM intervention.Conclusion: We achieved consensus among an international group of stakeholders on the OMERACT core domain set for rheumatology trials of SDM interventions. Future research will develop the Core Outcome Measurement Set.Clinical significance: Prior to this study, there had been no consensus on the OMERACT core domain set for SDM interventions. The current study shows that the OMERACT core domain set achieved a high level of endorsement by key stakeholders, including patients/caregivers, clinicians and researchers.(c) 2021 Elsevier Inc. All rights reserved.
AB - Objective: To gain consensus on the Outcome Measures in Rheumatology (OMERACT) core domain set for rheumatology trials of shared decision making (SDM) interventions.Methods: The process followed the OMERACT Filter 2.1 methodology, and used consensus-building methods, with patients involved since the inception. After developing the draft core domain set in previous research, we conducted five steps: (i) improving the draft core domain set; (ii) developing and disseminating whiteboard videos to promote its understanding; (iii) conducting an electronic survey to gather feedback on the draft core domain set; (iv) finalizing the core domain set and developing summaries, a plenary session video and discussion boards to promote its understanding; and (v) conducting virtual workshops with voting to endorse the core domain set.Results: A total of 167 participants from 28 countries answered the survey (62% were patients/caregivers). Most participants rated domains as relevant (81%-95%) and clear (82%-93%). A total of 149 participants (n = 48 patients/caregivers, 101 clinicians/researchers) participated in virtual workshops and voted on the proposed core domain set which received endorsement by 95%. Endorsed domains are: 1-Knowledge of options, their potential benefits and harms; 2-Chosen option aligned with each patient's values and preferences; 3-Confidence in the chosen option; 4-Satisfaction with the decision-making process; 5-Adherence to the chosen option and 6-Potential negative consequences of the SDM intervention.Conclusion: We achieved consensus among an international group of stakeholders on the OMERACT core domain set for rheumatology trials of SDM interventions. Future research will develop the Core Outcome Measurement Set.Clinical significance: Prior to this study, there had been no consensus on the OMERACT core domain set for SDM interventions. The current study shows that the OMERACT core domain set achieved a high level of endorsement by key stakeholders, including patients/caregivers, clinicians and researchers.(c) 2021 Elsevier Inc. All rights reserved.
KW - OMERACT
KW - Shared decision making
KW - Core domain set
KW - EULAR RECOMMENDATIONS
KW - ARTHRITIS
KW - MANAGEMENT
KW - FRAMEWORK
KW - AIDS
U2 - 10.1016/j.semarthrit.2021.03.017
DO - 10.1016/j.semarthrit.2021.03.017
M3 - Article
C2 - 33892937
SN - 0049-0172
VL - 51
SP - 593
EP - 600
JO - Seminars in Arthritis and Rheumatism
JF - Seminars in Arthritis and Rheumatism
IS - 3
ER -